AdaptHealth's Conference Tour Is About One Question: Did Execution Kill the Margin Story?

AdaptHealth announced on August 7 that CEO Suzanne Foster and CFO Jason Clemens will appear at the Canaccord Genuity Growth Conference in Boston on August 11 and the RBC Nashville Bus Tour on August 12. That is the kind of boilerplate press release every public company issues. But the timing matters. Three days earlier, on August 4, AdaptHealth reported one of the worst quarters in its history. The conference tour is not about growth — management already has that. It's about convincing investors the margin collapse is temporary rather than structural.

Let's start with the comparison set. AdaptHealth operates in the home medical equipment (HME) industry, competing against names like Apria Healthcare and Lincare. All of them face the same demographic tailwind — an aging population managing chronic conditions at home rather than in hospitals — but not all of them are simultaneously growing revenue and bleeding margin. AdaptHealth is. That combination is the question mark.

The growth story is still intact.

Continuing-operations revenue came in at $740.3 million in Q2, up 12.7% year-over-year. Organic growth — stripping out acquisitions — was 15.9%. That's strong for a company running 680 locations across 48 states. Sleep Health and Respiratory Health are the growth engines, and the capitated contract model (where insurers pay a fixed per-member rate rather than per-unit reimbursement) is working on the top line. AdaptHealth completed its first full quarter under a major West Coast capitated agreement with a national integrated delivery network, and signed a new deal with Humana OneHome covering approximately 478,000 members in South Florida and Texas.

The organic growth rate is the number that matters most if you believe AdaptHealth is a growth story that temporarily lost its way on execution. 15.9% organic expansion in an industry dominated by Medicare pricing and chronic-disease demographics is not easy to pull off.

The margin story is broken.

Adjusted EBITDA — earnings before interest, taxes, depreciation, and amortization, the closest proxy AdaptHealth has to operating cash generation — fell 3.2% to $132 million. On a $740.3 million revenue base, that's a 17.8% adjusted EBITDA margin. Not terrible in isolation, but it came after management slashed full-year EBITDA guidance from $680–730 million down to $490–520 million. The midpoint dropped $185 million in a single press release.

Operating margin, measured on a GAAP-adjacent basis, collapsed to -18.6%, down 26.5 percentage points from 9.9% in the same quarter last year. Free cash flow flipped from positive $73.3 million to negative $20.9 million. The stock dropped 25.7% the day earnings came out and has continued lower, trading near $5.70 as of August 7, well below both its 50-day moving average of $9.97 and its 200-day average of $10.35. The RSI sits at 17.5 — deeply oversold by any standard, indicating the selloff has been rapid and broad.

Management attributed the miss to three items: $55 million in costs from the West Coast capitated contract transition, $30 million from a manufacturer price increase, and $15 million from other portfolio actions. That's $100 million in one-time-adjacent charges eating margin on a $132 million EBITDA run-rate. If those are truly one-time, the underlying business is still generating roughly $232 million in adjusted EBITDA annually, or about 31% of the $740 million quarterly revenue run rate. If they recur — or if rapid growth through a new distribution model inherently carries higher costs — the margin math changes.

The diabetes divestiture is the structural pivot.

AdaptHealth entered into an agreement to sell its Diabetes Health business for $235 million in cash and is presenting it as discontinued operations. That divestiture alone accounts for $100 million of the guidance change, including $60 million of previously allocated corporate overhead that will now reflow to the remaining segments. In other words, the Sleep and Respiratory businesses have to absorb overhead they no longer share. The deal gives AdaptHealth a clearer thesis — sleep apnea and respiratory care are higher-margin, more recurring revenue streams — but the transition cost is real and it landed in Q2.

What the technical picture says about the market's current view.

The price action doesn't care about the growth narrative. At $5.70, AdaptHealth's market cap is roughly $1 billion, down sharply from the $1.44 billion level post-earnings. The MACD is deeply negative at -0.93, and the ATR (average true range, a volatility measure) sits at 0.70, meaning the stock is moving roughly 12 cents a day in either direction under current conditions. The market has reclassified this name from growth to distress.

That reclassification is the real thing the conference tour is responding to. Growth names don't usually trade at deeply oversold RSI levels with negative MACD crossossings. AdaptHealth is in technical territory that usually belongs to turnaround stories, not companies growing revenue at 15.9% organically.

The peer comparison gap.

I can't complete the standard peer read here. Apria Healthcare and Lincare don't have current structured data available in the system, so I'm working without a direct valuation or margin comparison set. That's a real limitation — in the HME space, margin profiles vary significantly based on capitated vs. fee-for-service mix, and AdaptHealth's 17.8% adjusted EBITDA margin could look rich or cheap depending on where the comparison set sits. The absence of that data means the margin judgment has to rest on AdaptHealth's own trajectory: adjusted operating margins have contracted 10.2 percentage points over five years and 9.4 percentage points over the last two. That's a pattern, not a blip.

What to watch at the conferences.

The specific question worth listening for: when do capitated contract margins come home? If management can articulate a credible timeline — two quarters, four quarters — for the West Coast transition costs to normalize, the conference appearances do the work of rebuilding the growth narrative. If the answer is vague or defensive, the stock's reclassification from growth to distress may be the more honest outcome.

The other signal is full-year free cash flow guidance of $80–120 million. That implies AdaptHealth expects Q3 and Q4 to generate enough cash to offset the negative $48.4 million year-to-date and still deliver positive full-year free cash flow. If Q3 doesn't turn the cash flow corner, the growth story and the cash generation story diverge further.

The bottom line.

AdaptHealth's conference tour is process noise for most investors — but it's the right process noise to pay attention to. The growth engine is running. The margin engine is misfiring. The stock has been repriced as if the growth engine is also in trouble. Whether that repricing is justified depends on a single question: are the execution costs of capitated contract transitions a one-time step or the new cost of doing business? Management will argue the former. The five-year margin trajectory suggests the latter deserves skepticism. The technical signals say the market has already voted.

In a barbell framework, this is a name that would belong on the growth-conviction side only after the next quarter's margin print confirms normalization. Until then, the factor stack — strong growth, deteriorating profitability, deeply oversold momentum — reads like a name that's trying to earn its way back into the growth sleeve rather than one that belongs there right now.